Category: Results

In this study, the Restore Vision team at Galway explored whether EVs from MSCs that were specially “trained” using two immune-related proteins  – TGF-β1 and IFN-γ –  could more effectively regulate the immune system than EVs from untrained cells. 

In this new study, our team at INSERM, explored whether mineralocorticoid receptor antagonists (MRAs)—commonly used for heart and kidney conditions—could aid corneal repair in limbal stem cell deficiency (LSCD), a rare and difficult-to-treat eye disease.

Research has shown that MSC-derived ApoBDs can help regulate the immune system, however they have not been studied as much as smaller extracellular vesicles. To fill in the gap, our team at Galway conducted a study to explore the therapeutic potential of large and small ApoBDs.

In this new article, our team at the University of Galway reviewed and analysed current research on the use of MSCs and MSC-EVs in treating corneal diseases.

Restore Vision has conducted the first comprehensive review of FDA-approved excipients in ophthalmic medications, examining their roles, safety, and the regulatory pathways required for approval for human use.

At the recent ARVO meeting, Wei Zhang presented the latest findings from the University of Cologne on a new treatment to regress corneal neovascularization in mice

At the recent ARVO meeting, Karina Hadriaan presented the latest findings from the University of Cologne on a new treatment to regress corneal neovascularization in mice

At the recent ARVO meeting, Daniela Braz presented the latest findings from INSERM on the development of a new eye drop to treat cornea wounds in mice.

At the recent ARVO meeting, Raquel Gregorio presented the latest findings from INSERM on the use of spironolactone for treating corneal diseases.

At the recent ARVO meeting, Meert Mestanoglu presented UKK’s ongoing research on a novel combination treatment for corneal vessel regression.